Loading
A phase 3 trial of Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine and Intismeran autogene in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) is a phase 3 interventional study registered as NCT06623422 by Merck Sharp & Dohme LLC, with 680 participants planned, started 2024-10-21 and due to reach its primary completion in 2033-05-16. Interventions recorded: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine and Paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Merck & Co. (MSD), Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, Merck & Co. (MSD), Gemcitabine, Cisplatin and the tag pipeline.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/